{
    "nct_id": "NCT05112536",
    "official_title": "A Phase 2, Open-Label, Single-Arm Study of Single-Dose Lead-In and Neoadjuvant Trilaciclib and Chemotherapy in Patients With Early-Stage Triple Negative Breast Cancer (TNBC)",
    "inclusion_criteria": "* Suitability of therapy and patient intends to undergo curative surgery\n* Documented diagnosis of estrogen receptor (ER)-negative and progesterone receptor (PR)-negative tumor\n* Primary tumor ≥ 1.5 cm with any nodal status\n* Provide archival tissue for the baseline tissue sample\n* ECOG performance status of 0 or 1\n* Demonstrates adequate organ function\n* Research tumor biopsies including at least one on-treatment biopsy (and additional biopsy at baseline, if required)\n* Participants of child bearing potential must be willing to use 2 forms of contraception during the study and for 6 months following study treatment\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior systemic therapies or radiation for current breast cancer\n* History of invasive malignancy ≤3 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer\n* History of breast cancer including ipsilateral ductal carcinoma in situ (DCIS) treated with radiotherapy at any time\n* Previous exposure to doxorubicin of more than 200 mg/m2 (as lifetime exposure to doxorubicin is not to exceed 450 mg/m2)\n* For patients who will receive pembrolizumab:\n\n  * History of active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy is not considered a form of systemic treatment\n  * Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drugs\n* History of (non-infectious) pneumonitis that required steroids or current pneumonitis\n* Known history of active tuberculosis (Bacillus Tuberculosis)\n* History of severe hepatic impairment\n* Uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart failure (Class II-IV as defined by the New York Heart Association [NYHA] functional classification system)\n* Known history of stroke, cerebrovascular accident, severe/unstable angina, myocardial infarction, or coronary angioplasty/stenting/bypass grafting within 6 months prior to enrollment\n* Known serious active infection (e.g., human immunodeficiency virus [HIV], hepatitis B or C, tuberculosis).\n* Women who are pregnant or breastfeeding\n* Participation in other studies involving active treatment with investigational drug(s)\n* Prior hematopoietic stem cell or bone marrow transplantation",
    "miscellaneous_criteria": ""
}